Blanc P.J., Loret M.O., Santerre A.L., Pareilleus A., Prome D., Prome J.C., Laussac J.P., Goma G. (1994) J. Food Sci..59: 862-865.
Blanc,P. J., Loret, M. O. and Goma, G. (1995) Biotechnology Letters
.17(3):291-294.
Brown, M. S. and J. L, Goldstein,. (1984).How LDL receptors influence
cholesterol and atherosclerosis. Scientific American, 251(5) :52-60.
Bucher M, Mair G, Kees F. (2002);Effect of roxithromycin on thr pharmacokinetics of lovastatin in volunteers.Eur J Clin Pharmacol.57:787-791.
Endo, A., Kuroda, M. and Tusija, (1976);Y. ML-336, ML-236B and
ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. Journal of Antibiotics.29: 1346-1348.
Endo, A., (1979);Monacolin K, a new hypocholesterolemic agent produced by
Monascus species. The Journal of Antibiotics.32 :852-854.
Endo, A., D. Komagata, and H. Shimada, (1986).Monacolin M, a new
inhibitor of cholesterol biosynthesis.
Fears, R., (1983).Pharmacological control of 3-Hydroxy-3-Methylglutaryl Coenzyme A reductase. In 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Sabine, J. R., Ed, 189-208, CRC Press, Inc., Boca Raton.
Frishman, W .H., Zimetbaum, P., and Nadelmann, J. (1989)., Lovastatin and other HMG-CoA reductase inhibitors, J. clin. pharmacol, 29: 975-982.
Fink-Gremmels, J., Dresel, J. and Leistner, L. (1991); Monascus-extrakten als nitrat-alternative bei fleischerzeugnissen [Use of Monascus extracts as an alternative to nitrite in meat products]. Fleischwirtschaft. 71: 329-331.
Hauck WW,Anderson S. (1984); A new statistical procedure for testing equivalence in two-group comparative bioavailability trials, J pharmacokin Biopharm.;12:83-91.
Halpin, R.A., Ulm, E.H., Till, A.E.,Kari, P.H., Vyas, K.P.,Hunningkake, D.B.
and Duggan, D.E. (1993)., Biotransformation of lovastatin: species di erences in invivo metabolite pro les of mouse, rat, dog, and human, Drug metab. Dispos., 21, 1003-1011.
Hong Wang, Yunhui Wu and Zhongxi Zhao (2001). Journal of mass spectrometry.Fragmentation study of simvastatin and lovastatin
using electrospray ionization tandem mass spectrometry; 36: 58–70.
Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. Feb;69(2):231-6
Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. . (2001)
An analysis of nine proprietary Chinese red yest rice dietary supplements:
implications of variability in chemical profile and contents.
J Altern Complement Med. Apr ;7(2):133-9.
Huang HN, Hua YY, Bao GR, Xie LH.(2006) ;The quantification of monacolin K in some red yeast rice from Fujian province and the comparison of the other product. Chem Pharm Bull (Tokyo). May;54(5):687-9
Igel M, Sudhop T, Bergmann KV. (2002); Pharmacology of 3-hydroxy-3
-methylglutarylcoenzyme a reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol; 42: 835-45.
Jui-Yun Fan(2004) ; Effects of Solid Fermentative Products of Sweet Potato
with peels by Monascus spp. on the Expression of Microsome
Triglyceride Transfer Protein in HepG2 cells and Blood Lipid profiles in
Wistar Rats.-Graduate Institute of Food and Nutrition Shih Chien
University.
Juzlova, P., Martinkova, L. and Kren, V. (1996); Secondary metabolites of the
fungus Monascus: a review. Journal of Industrial Microbiology
.16:163-170.
Journoud M, Jones PJ. (2004) ;Red yeast rice: a new hypolipidemic drug. Life Sci. Apr 16;74(22):2675-83.
Laranjinha J., Vieira O., Almeida L. and Maderia V. (1996);Inhibition of
Metmyoglobin/H2O2-Dependent Low Density Lipoprotein Lipid.
Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ, Heber D. (2005)
Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med.Dec;.11(6):1031-8
Munro, E., Patel, M., Chan, P., Betteridge, L., Clunn, G., Gallagher, K.,
Hughes, A.,Schachter, M., Wolfe, J.,Sever, P. S., (1994) Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of
isoprenoid intermediates of cholesterol synthesis, Eur. J. clin. invest.,
.24: 766-772
Nil, (1995 a). SSRI: unprecedented US Growth, Scrip, 2024 : 23.
Nil, ( 1995 b).Yen Effect on Japan’s Pharma Market, Scrip, 2023 : 22.
Patakova-Juzlova, P., Rezanka, T. and Viden, I. Identification of
volatile metabolites from rice fermented by the fungus Monascus
purpureus (an-kak). Folia Microbiologica (1998). 43: 407-410.
Stein EA, Lane M, Laskarzewski P. (1998);Comparison of statins in
hypertriglyceridemia.Am J Cardiol; 81: 66-9.
Statins and Liver Toxicity: A Meta-Analysis, Simon de Denus, M.Sc., Sarah
A.Spinler, Pharm.D., FCCP, Kristin Miller, Pharm.D., and Andrew M.
Peterson, Pharm.D. Pharmacotherapy; (2004)24 (5) : 584-591;
Westlake WJ.Response to Kirkwood,TBL.:Bioequivalence testing-a need to
rethink.Biometrics; (1981). 37:589-594.
Wild D, Toth G, Humpf HU. (2002); New monascus metabolite isolated from red yeast rice (angkak,red koji). J Agric Food Chem.
Jul 3;50(14):3999-4002.
Ying, J., Mao, X., Ma, Q. et al. Icones of Medicinal Fungi from
China.Beijing, China: Science Press, (1987). pg. 9.
Yang H, Feng Y, Luan Y ;(2003) Determination of Simvastatin in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. Mar 5;785(2):369-75
Zhao JJ, Yang AY, Rogers JD. (2002)Effects of liquid chromatography mobile phase buffer contents on the ionization and Fragmentation of analytes in liquid chromatographic/ionspray tandem mass spectrometric
determination.JmassSpectrom. Apr;37(4):421-33.
王雲萍、張永吉(1996)，文明產物－降血脂劑Lovastatin。化工資訊，10(4)：53-57。
李昭蓉 (1997) 漫談紅麴菌。食品工業月刊，29(2):86-89.林讚峰 (1992) 以紅麴菌的膽固醇抑制劑為範例說明酵素合成抑制劑的開發應用及生產。製酒科技專論彙編 ，14:263-281林讚峰 (1994) 紅麴菌的特性及應用。生物產業，5:29-35林讚峰 (1992) 紅麴菌研究發展之演進。科學農業，40(3-4):193-198.林讚峰 (1985) 紅麴菌培養工藝及紅麴應用之演進。製酒科技專論
彙，156-168。
林讚峰 (1983) 紅麴菌的鑑定及實用分類法。製酒科技專論彙編，5:104-113.
徐茂輝 (1999) 傳統紅麴及功能紅麴的研究開發與進展。食品資訊，
162:14-19.
趙海和徐茂輝 (2002) 從紅麴及其相關產品的歷史談開發現狀與面臨
的挑及發展前景。食品資訊，183:56-61
鄭顏昆，2001。甲硫胺酸與乙酸鈉對紅麴生產膽固醇合成抑制劑產量
影響之研究，大葉大學食品工程研究所碩士論文
鄭子彥，2003。紅麴citrinin 定量分析方法之研究，國立台灣大學農業化學研究所碩士論文。
蘇遠志、陳文亮、方鴻學、翁浩慶、王文祥 (1970) 紅麴菌( Monascus anka) 之菌研究 。中國農業化學誌 ，8: 46-54。